Dentsply Sirona Inc. ( XRAY ) shares are trading lower on Thursday.

The company reported fourth-quarter adjusted earnings per share of 26 cents, missing the street view of 43 cents.

Quarterly sales of $905 million (down 10.6% year over year) missed the analyst consensus estimate of $920.56 million. Organic Sales fell 10.7% year over year.

Adjusted EBITDA slumped 25.9% to $128 million, while adjusted EBITDA margin contracted to 14.2% from 17.1% in the year-ago period.

“While we were pleased to see improvement in several areas of the business, Byte, persistent macro pressures and competitive dynamics negatively impacted Q4 and 2024 full year results,” said Simon Campion, President and Chief Executive Officer.

Also Read: Trump Shuts Down Chevron’s Venezuela Oil Permit, Tightening Pressure On Maduro Regime: Crude Oil Prices Rise On Supply Concerns

In the fourth quarter, the company paid $31 million in dividends, resulting in a total of $376 million returned to shareholders through dividends and share repurchases in 2024.

The company had $272 million of cash and cash equivalents as of December 31, 2024.

“Improvements in Q4 included a return to growth in Europe and imaging globally, as well as continued growth of Wellspect Healthcare and SureSmile,” Campion adds.

Dividend: On February 26, the company declared a quarterly cash dividend of $0.16 per share of common stock, an indicated annual rate of $0.64 per share.

The dividend is payable on April 11 to holders of record as of March 28.

Outlook: Dentsply Sirona ( XRAY ) expects 2025 sales between $3.5 billion and $3.6 billion, below the consensus of $3.734 billion.

Organic sales are projected to decline by 2.0% to 4.0%, including a 2% impact from Byte sales.

The company anticipates adjusted EPS to range from $1.80 to $2.00, compared with the consensus of $1.90.

Price Action: XRAY shares are trading lower by 6.80% to $17.53 at last check Thursday.

Also Read:

Photronics Q1 Earnings: Beats Estimates, Strong IC And FPD Demand, Growth in High-End Products, CEO Cautious on 2025 Outlook

Image via Shutterstock.